Patient demographics with disease, type, and duration of prior bisphosphonate intake, histology, and location/region of BONJ

Patient	Sex	Age (yr)	Disease	Bisphosphonate	Duration of Treatment	Histology	Region
1	F	56	Metastases, breast Ca	Zoledronic acid (Zometa)	54 mo	ON/OM	23–28
2	F	85	MM	Zoledronic acid (Zometa)	48 mo	ON/OM	44–46
3	F	64	MM	Zoledronic acid (Zometa)	48 mo	ON	34–37
4	F	60	Metastases, breast Ca	Zoledronic acid (Zometa)	48 mo	ON	35–36 and 45
5	F	59	Metastases, mamma Ca	Zoledronic acid (Zometa)	36 mo	ON	14–17
6	F	53	Osteoporosis	Ibandronic acid (Bondronat oral)	12 mo	ON	45–47
7	F	86	Osteoporosis	Ibandronic acid (Bondronat oral)	Not available	ON	45–47
8	F	79	Metastases, breast Ca	Zoledronic acid (Zometa)	7 mo	ON	11–15
9	M	66	MM	Zoledronic acid (Zometa)	60 mo	ON	14–15
10	F	88	Metastases, breast Ca	Zoledronic acid (Zometa)	Not available	Not operated	17–18

Note:—ON indicates osteonecrosis; OM, osteomyelitis; MM, multiple myeloma; Ca, cancer; Mamma, mammary.